Healios KK
TSE:4593

Watchlist Manager
Healios KK Logo
Healios KK
TSE:4593
Watchlist
Price: 653 JPY -2.1%
Market Cap: 68.4B JPY

Operating Margin
Healios KK

-431.5%
Current
-4 834%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-431.5%
=
Operating Profit
-2.5B
/
Revenue
588m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
JP
Healios KK
TSE:4593
66.3B JPY
-431%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
337.7B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
163.2B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
142.2B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
132.5B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.4B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Healios KK
Glance View

Market Cap
66.3B JPY
Industry
Biotechnology

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Intrinsic Value
359.79 JPY
Overvaluation 45%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-431.5%
=
Operating Profit
-2.5B
/
Revenue
588m
What is the Operating Margin of Healios KK?

Based on Healios KK's most recent financial statements, the company has Operating Margin of -431.5%.

Back to Top